Before discontinuing Rybelsus, arrange an appointment with your GP or diabetes care team to discuss: Your reasons for wanting to stop the medication Current diabetes control (recent HbA1c, fasting glucose readings) Alternative treatment options or adjustments to existing medications Monitoring plan for blood glucose levels after discontinuation Dietary and lifestyle strategies to maintain glycaemic control Your healthcare provider may recommend: Alternative medications : Depending on your diabetes control and other health factors, you may need to start or increase doses of other glucose-lowering agents such as metformin, SGLT2 inhibitors, DPP-4 inhibitors, sulfonylureas, or insulin
Common adverse effects include: Gastrointestinal symptoms (nausea, vomiting, diarrhoea, constipation)usually transient and dose-dependent Injection site reactions Fatigue and dizziness Potential risk of gallbladder problems Thyroid C-cell tumours (observed in rodent studies
Every three to four months is a reasonable starting schedule
Savings cards from the manufacturer Novo Nordisk Canada runs the NovoCare patient-support program for Wegovy
This was a randomized, head-to-head comparison that enrolled 751 individuals and found those who took tirzepatide lost 20% of their body weight, about 50 pounds on average, while those on semaglutide lost 14% of their body weight, or about 33 pounds on average
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept